MDR 103

Drug Profile

MDR 103

Alternative Names: MDR-103

Latest Information Update: 17 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medeor Therapeutics
  • Class Cell therapies; Immunotherapies; Stem cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Renal transplant rejection

Most Recent Events

  • 11 May 2017 Medeor Therapeutics plans a phase II trial for Renal transplant rejection (In existing living donor kidney transplant recipients) in USA (Medeor Therapeutics' website, May 2017)
  • 11 May 2017 Phase-I clinical trials in Renal transplant rejection in USA (Parenteral) (Medeor Therapeutics' website, May 2017)
  • 28 Apr 2017 Medeor Therapeutics has patent protection for technology underlying the manufacturing process of its therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top